RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New study tests Twice-Daily radiation to boost T-Cell attack on lymphoma
Disease control Recruiting nowThis study tests a new way to give radiation before T-cell therapies (CAR T or bispecific antibodies) for people with relapsed or refractory diffuse large B-cell lymphoma. Each participant's tumor is split in half: one side gets once-daily radiation, the other gets twice-daily ra…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Phase: NA • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug aims to wipe out cancer protein in Tough-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new oral drug, BGB-16673, designed to destroy a protein called BTK that helps certain blood cancers grow. The trial includes about 645 people with various B-cell cancers (like lymphoma and leukemia) that have come back or not responded to prior treatments. The …
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New CAR T-Cell therapy aims to tackle tough lymphoma
Disease control Recruiting nowThis phase 2 trial tests a new treatment called MB-CART2019.1 for people with a type of aggressive lymphoma (DLBCL) that has come back or not responded to treatment. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer c…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New CAR-T therapy targets BAFF-R to fight resistant lymphoma
Disease control Recruiting nowThis early-phase trial tests a new treatment called BAFF-R CAR-T for people with B-cell lymphoma that has come back or stopped responding to standard therapy. The treatment uses a patient's own immune cells, modified to find and attack cancer cells carrying a protein called BAFF-…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New immune cell combo tackles tough lymphoma
Disease control Recruiting nowThis study tests whether a special type of immune cell (ONC-PluReceptor NK cells) given with two antibody drugs (epcoritamab and tafasitamab) can control B-cell Non-Hodgkin lymphoma that has come back or not responded to prior treatments. About 30 adults aged 18-80 who have alrea…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New injection shows promise for tough lymphoma cases
Disease control Recruiting nowThis early-phase study tests a new drug called KSV01 in 18 adults with relapsed or refractory diffuse large B-cell lymphoma, a type of blood cancer that has not responded to standard treatments. The main goal is to check the safety of the injection and find the best dose. Partici…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New pill plus chemo aims to tackle tough lymphoma
Disease control Recruiting nowThis Phase 3 trial tests whether adding an experimental pill (HMPL-760) to standard chemotherapy (R-GemOx) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). About 240 adults will be randomly assigned to get either the new drug or a placebo, plus chem…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New combo aims to boost transplant success in tough lymphoma
Disease control Recruiting nowThis study tests a combination of two chemotherapy drugs (gemcitabine and oxaliplatin) plus a low dose of the immunotherapy epcoritamab in 10 people whose diffuse large B-cell lymphoma has come back or not responded to prior treatment. Participants must be eligible for a stem cel…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Hospital Universitario Dr. Jose E. Gonzalez • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for tough lymphoma: glofitamab trial launches in china
Disease control Recruiting nowThis study tests a drug called glofitamab in 20 Chinese patients whose diffuse large B-cell lymphoma has returned or not responded to at least two prior treatments. The goal is to see if the drug can control the cancer and how safe it is. Participants receive glofitamab alone, an…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Radiation boost may help CAR-T cells wipe out stubborn lymphoma
Disease control Recruiting nowThis study tests whether giving a special type of radiotherapy (ultra-fraction) before CAR-T cell therapy can safely improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma. About 20 adults who have failed at least two prior treatments will receive t…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Phase: NA • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New pill targets Hard-to-Treat lymphoma in first human trial
Disease control Recruiting nowThis early-stage trial tests an experimental drug called ARV-393 in 255 adults with advanced non-Hodgkin's lymphoma that has come back or not responded to other treatments. The drug is taken as a pill and works by breaking down a protein that helps lymphoma grow. The main goals a…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Real-World data on glofitamab shows promise for Tough-to-Treat lymphoma
Knowledge-focused Recruiting nowThis study looks back at medical records of about 250 adults with large B-cell lymphoma who received the drug Glofitamab through a special access program in France. The goal is to see how well the drug works and what side effects occur in everyday practice, especially in patients…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Sponsor: The Lymphoma Academic Research Organisation • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC